Tislelizumab combined with chemotherapy shows promising antitumor activity in advanced cervical cancer, achieving high response rates and manageable safety profiles.

Adjuvant camrelizumab and concurrent chemoradiotherapy can improve outcomes in patients with gallbladder cancer and extrahepatic cholangiocarcinoma.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival ...

Upper GI cancer treatment depends on a number of factors, and may include treatments such as surgery, chemotherapy, radiation ...

David Spigel, MD, medical oncologist and the chief scientific officer at Sarah Cannon Research Institute in Nashville, Tennessee, discusses the pivotal findings from the AIM-HIGH trial (NCT01817192), ...

Pathologic complete response was accurately predicted by post-treatment MRI in patients with breast cancer who received ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based tests to inform decisions about adjuvant chemotherapy for patients with a ...